Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $49.20 ($740K) on 2026-04-01, disclosed to the SEC on 2026-04-03.
Scheduled sale ($740k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.20 | 12,344 | $607K | 82.1% |
| 2 | $49.92 | 2,656 | $133K | 17.9% |
| Total | $49.33 avg | 15,000 | $740K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |